Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 27, 2000

View Archived Issues

Vivus signs Muse marketing agreement with Paladin for Canada

Company Profile: Myogen

Synsorb updates product developments at BIO-Europe

Angiotech begins phase II trial with micellar paclitaxel for psoriasis

Preclinical data show NO-aspirin efficacy in preventing vein graft failure

Patient enrollment and initial treatment completed in PRESTO trial

Milestone reached in Aventis/PPD Discovery new drug development alliance

AxyS Pharmaceuticals reports third quarter progress and product update

BioNumerik and Grelan create new company focused on anticancer therapies

Introgen's gene therapy shows significant proapoptotic activity in preclinical studies

Significant activity seen for squalamine in phase II lung cancer trial

MGI Pharma and MethylGene begin phase II evaluation of MG-98 in head and neck cancer

Company Profile: Intercell

Immunosuppressive profile of FTY-720 further defined in preclinical studies

Heparan sulfate useful for inducing dendritic cell maturation for mounting a primary immune response

Enhanced antifungal activity of FK-463-amphotericin B combination

In vitro antifungal activity of NND-502 highlighted at Nagasaki meeting

Novel steroidal aromatase inhibitor TZA-2237 tested in dog models of BPH

FKBP Ligands: Novel Strategies for the Treatment of Neurodegenerative Disorders

Servier compares in vitro/in vivo antitumor activity of new olivacines to doxorubicin and VP-16

Webcasts from AHA Scientific Sessions now available

RTI and NIDA identify first potent, selective NET ligand from 3-phenyltropane series

Novel pharmaceutical compositions prepared for rosiglitazone

Modulators of metabotropic glutamate receptors disclosed by Roche

R&D at Sanofi-Synthelabo leads to identification of potent PDE5 inhibitors

Novel cyclic tyrosine kinase inhibitors reported by BMS scientists

Novel class of H3 antagonists identified through Novo Nordisk/Boehringer Ingelheim collaboration

Roche's new antiinflammatory agents inhibit alpha4 integrin binding

New gastric antisecretory agents patented by Byk Gulden

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...